Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients.

ABSTRACT: To evaluate safety and clinical outcomes of extracorporeal immunomodulation treatment with a selective cytopheretic device (SCD) in COVID-19 ICU patients with multiple organ failure.

Design

Two-center, prospective, single-arm treatment clinical trial.

Setting

ICUs at two academic medical centers between September 2020 and July 2021.

Patients

Twenty-two COVID-10 patients in the ICU with acute respiratory distress syndrome who required mechanical ventilation. Nearly all included patients in the intervention group except one had acute kidney injury requiring continuous renal replacement therapy (CRRT). Sixteen subjects meeting enrollment criteria were selected as contemporaneous controls from a concurrent prospective registry CRRT trial.

Intervention

Treatment with

SUBMITTER: Yessayan LT 

PROVIDER: S-EPMC9126516 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature